Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity

Samikshya Santosh Nirmala, Kayani Kayani, Mateusz Gliwiński, Yueyuan Hu, Dorota Iwaszkiewicz-Grześ, Magdalena Piotrowska-Mieczkowska, Justyna Sakowska, Martyna Tomaszewicz, José Manuel Marín Morales, Kavitha Lakshmi, Natalia Maria Marek-Trzonkowska, Piotr Trzonkowski, Ye Htun Oo, Anke Fuchs*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

126 Downloads (Pure)

Abstract

The initial idea of a distinct group of T-cells responsible for suppressing immune responses was first postulated half a century ago. However, it is only in the last three decades that we have identified what we now term regulatory T-cells (Tregs), and subsequently elucidated and crystallized our understanding of them. Human Tregs have emerged as essential to immune tolerance and the prevention of autoimmune diseases and are typically contemporaneously characterized by their CD3+CD4+CD25high CD127lowFOXP3+ phenotype. It is important to note that FOXP3+ Tregs exhibit substantial diversity in their origin, phenotypic characteristics, and function. Identifying reliable markers is crucial to the accurate identification, quantification, and assessment of Tregs in health and disease, as well as the enrichment and expansion of viable cells for adoptive cell therapy. In our comprehensive review, we address the contributions of various markers identified in the last two decades since the master transcriptional factor FOXP3 was identified in establishing and enriching purity, lineage stability, tissue homing and suppressive proficiency in CD4+ Tregs. Additionally, our review delves into recent breakthroughs in innovative Treg-based therapies, underscoring the significance of distinct markers in their therapeutic utilization. Understanding Treg subsets holds the key to effectively harnessing human Tregs for immunotherapeutic approaches.
Original languageEnglish
Article number1321228
JournalFrontiers in immunology
Volume14
DOIs
Publication statusPublished - 12 Jan 2024

Bibliographical note

Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding for publication was received from ‘‘The Saxon State and University Library (SLUB), Dresden’’. SS and YH are funded by the German Federal Ministry of Education and Research under the funding code 03ZU1111AA as part of the Cluster4Future, SaxoCell. JM, KL, and AF are funded by Mildred Scheel Early Career Center (MSNZ), German Cancer Aid (Deutsche Krebshilfe, DKH). KK and YO are funded by Sir Jules Thorn Biomedical Research Charity, London. KK is funded by the National Institute for Health and Care Research (NIHR). NM-T is supported by the project “International Centre for Cancer Vaccine Science” that is carried out within the International Research Agendas Programme of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund. NM-T is supported by the project “International Centre for Cancer Vaccine Science” that is carried out within the International Research Agendas Programme of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund (MAB/2017/3).

Keywords

  • regulatory T cells
  • Treg markers
  • Treg heterogeneity
  • Treg chemokine receptors
  • Treg therapy
  • FOXP3
  • Treg function

Fingerprint

Dive into the research topics of 'Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity'. Together they form a unique fingerprint.

Cite this